Get the Stockscreener App
1.69
1.74%
-0.03
After Hours:
1.70
0.01
+0.59%
Xortx Therapeutics Inc stock is traded at $1.69, with a volume of 46,569.
It is down -1.74% in the last 24 hours and down -25.22% over the past month.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
See More
Previous Close:
$1.72
Open:
$1.74
24h Volume:
46,569
Relative Volume:
0.25
Market Cap:
$3.07M
Revenue:
-
Net Income/Loss:
$-2.77M
P/E Ratio:
-0.6386
EPS:
-2.6464
Net Cash Flow:
$-2.69M
1W Performance:
-11.98%
1M Performance:
-25.22%
6M Performance:
-11.52%
1Y Performance:
-60.70%
1-Day Range:
$1.69
$1.82
1-Week Range:
$1.69
$2.09
52-Week Range:
$1.5901
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
1.69 | 3.07M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
Why XORTX Therapeutics Inc. (NASDAQ:XRTX) Is In Focus Now? - Kalkine Media
XRTX Jumps As XORTX Advances XORLO Gout Program Plans - timothysykes.com
XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis - kalkine.ca
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
XORTX plans FDA IND filing for XRx-026 gout program - grafa.com
XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing - StocksToTrade
XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Therapy - tipranks.com
A potential new gout pill targets a $700M market as XORTX Therapeutics (XRTX) details its FDA game plan - Stock Titan
XORTX Therapeutics Plans Q4 2026 FDA IND Submission for XRx-026 Gout Program Using XORLO™, Eyes US$700M Market - kalkine.ca
Vectus Biosystems Releases FY2026 Annual Report, Details CEO Appointment and VB0004 Development - kalkine.com.au
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Shares Rise 16.11% After HoursXORTX Therapeutics (NASDAQ:XRTX) - Benzinga
XORTX Therapeutics Initiates GMP Manufacturing of XORLO™ to Advance Gout Treatment Clinical Trials - Kalkine Media
Xortx Therapeutics Inc Announces the Launch of Production of Drug Material and Tablet Manufacturing - marketscreener.com
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program - TipRanks
XORTX Therapeutics (XRTX) begins making new gout drug - Stock Titan
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - The Manila Times
XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist - Stock Titan
Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
Price to earnings forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
EBITDA margin % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - The Globe and Mail
XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView
Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages Investor Relations Program - markets.businessinsider.com
XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView
XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - kalkinemedia.com
Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView
Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView
Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - ad-hoc-news.de
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Announces Termination and Postponement of Investor Relations Program - marketscreener.com
XORTX Therapeutics Inc. (XRTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
XORTX Therapeutics Inc. (XRTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - Stock Titan
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics (TSXV:XRTX) Shares Jump 10.8% in a Volatile Session - kalkine.ca
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks
Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):